114-86-3
114-86-3
Chemical Structure
Phenformin
Synonym(s): Phenethylbiguanide
- CAS No.: 114-86-3
- Formula:C10H15N5
- Molecular Weight:205.26
InChIKey: ICFJFFQQTFMIBG-UHFFFAOYSA-N
SMILES: NC(NC(NCCC1=CC=CC=C1)=N)=N
Biological Activity: Phenformin (Phenethylbiguanide) is an orally active biguanide hypoglycemic agent. Phenformin inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin inhibits cancer stem cells (CSCs) and possesses potent antitumor potential[1][2][3][4].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Phenformin | 98.02% | Phenformin (Phenethylbiguanide) is an orally active biguanide hypoglycemic agent. Phenformin inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin inhibits cancer stem cells (CSCs) and possesses potent antitumor potential. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phenformin (Standard) | ≥98% | Phenformin (Phenethylbiguanide) (Standard) is the analytical standard of Phenformin (HY-16397). This product is intended for research and analytical applications. Phenformin (Phenethylbiguanide) is an orally active biguanide hypoglycemic agent. Phenformin inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin inhibits cancer stem cells (CSCs) and possesses potent antitumor potential. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
m-Iodobenzylguanidine | ≥97.0% | m-Iodobenzylguanidine (Iobenguane) is a ligand with high affinity against norepinephrine transporter (NET). m-Iodobenzylguanidine is used as an imaging agent in the diagnostic imaging and radionuclide studies of neuroendocrine tumors, such as neuroblastoma, pheochromocytoma and carcinoid tumor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Methylphenethylamine | 98.89% | N-Methylphenethylamine is an indirectly acting sympathomimetic amine that is formed via PNMT-catalyzed N-methylation of phenethylamine (PEA) in the human body. N-Methylphenethylamine exhibits affinity for β-adrenergic receptors on the surface of cancer cells or bacterial cells. N-Methylphenethylamine can be used for neurotransmitter research or as a pharmaceutical intermediate. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Methylphenethylamine hydrochloride | N-Methylphenethylamine (NMPEA) hydrochloride is a potent TAAR1 agonist. N-Methylphenethylamine hydrochloride also is a trace amine neuromodulator. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Benzylethylenediamine | 99.79% | N-Benzylethylenediamine is a polyamine compound. N-Benzylethylenediamine can effectively release Ca2+ from the outer membrane of Escherichia coli (ED50: 200-500 μM), but cannot induce TPP+ uptake. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Benzylurea (Standard) | ≥98% | Benzylurea (Standard) is the analytical standard of Benzylurea (HY-W010253). This product is intended for research and analytical applications. Benzylurea is a benzylamide. Benzylurea is an anti-inflammatory agent. Benzylurea inhibits LPS (HY-D1056)-induced upregulation of MTCH2 expression and regulates pathways associated with mitochondrial function, inflammation and cell survival. Benzylurea alleviates LPS-induced proliferation inhibition and apoptosis of periodontal ligament fibroblasts, as well as the release of proinflammatory cytokines. Benzylurea can be used in studies related to periodontitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phenylacetylglycine (Standard) | 99.38% | Phenylacetylglycine (Standard) is the analytical standard of Phenylacetylglycine. This product is intended for research and analytical applications. Phenylacetylglycine is a gut microbial metabolite that can activate β2AR. Phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Methyl-3-phenylpropan-1-amine (Standard) | 98.65% | N-Methyl-3-phenylpropan-1-amine (Standard) is the analytical standard of N-Methyl-3-phenylpropan-1-amine. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3-Phenylpropionamide | 3-Phenylpropionamide is a ω-phenylalkylamide organic compound. 3-Phenylpropionamide can be used as an intermediate in the synthesis of chlorinated aromatic amide compounds. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Benzylacetamidine hydrobromide | N-Benzylacetamidine (hydrobromide) is a acetamidine compound. N-Benzylacetamidine (hydrobromide) is a selective inducible nitric oxide synthase (iNOS) inhibitor with an IC50 of 0.20 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(2-Phenylethyl)hydrazine dihydrochloride | (2-Phenylethyl)hydrazine (dihydrochloride) is a compound with protective effects against γ-radiation. At a dose of 60 mg/kg, it can increase the survival rate of mice exposed to γ-radiation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. García Rubiño ME, et al. Phenformin as an Anticancer Agent: Challenges and Prospects. Int J Mol Sci. 2019;20(13):3316. Published 2019 Jul 5. [Content Brief]
- [2]. Alves-Silva AB, et al. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Invest New Drugs. 2022;40(3):576-585. [Content Brief]
- [3]. Hu S, et al. Phenformin inhibits cell proliferation and induces cell apoptosis and autophagy in cholangiocarcinoma. Mol Med Rep. 2018;17(4):6028-6032. [Content Brief]
- [4]. Yendapally R, et al. A review of phenformin, metformin, and imeglimin. Drug Dev Res. 2020;81(4):390-401. [Content Brief]
